Life Sciences

Successful Phase 3 Trials Propel Innovent’s Mazdutide i...

Innovent, a prominent player in the Chinese pharmaceutical landscape, is gearing...

In phase 2 head-to-head comparison, Curevo’s shingles v...

Curevo Vaccine’s bold strategic move to enter the competitive Shingles vaccine m...

Global Approval in the future for AstraZeneca’s Infant ...

AstraZeneca and Sanofi achieved a milestone as their respiratory syncytial virus...

Roche Study Finds Novel Antibiotic Targets Drug-Resista...

Researchers have made a significant breakthrough in the fight against antibiotic...

Novartis signs a $100 million upfront gene therapy agre...

Novartis announced an expansion of its collaborative efforts with Voyager Therap...

Roche buys Point-of-Care Technology Platform from LumiraDx

Swiss pharmaceutical company Roche announced its agreement to acquire LumiraDx’s...

Otsuka and Ionis Pharmaceuticals partner for  Hereditar...

Japanese pharmaceutical company Otsuka Pharmaceutical has entered into a signifi...

Gilead Sciences Secures Exclusive Rights in $848 Millio...

Gilead Sciences has concluded a significant transaction with Compugen, securing ...

Pivotal Bio Venture Partners closes $389 million fund, ...

Pivotal bioVenture Partners has successfully concluded its second fund, securing...

GSK returns to Hansoh and pays $185 million upfront for...

The ongoing surge of interest in antibody-drug conjugates (ADCs) remains unabate...

Compass Unveils Safety Data For Psilocybin Phase 2 PTSD...

In less than a week following the submission of the historic first request for a...

Sanofi forced to abandon Lead ADC Tusamitamab Ravtansin...

Sanofi, a prominent figure in the pharmaceutical realm, finds itself grappling w...

FDA approves Wainua for Rare Disease Treatment

In a milestone announcement, the U.S. Food and Drug Administration (FDA) has gra...

Ionis and AstraZeneca drug gains FDA approval for Hered...

Ionis Pharmaceuticals and AstraZeneca are capping off the year with a notable ac...

AbbVie to Shell Out $8.7B to Purchase Cerevel

AbbVie has entered into an agreement to purchase Cerevel Therapeutics for $8.7 b...

Jazz Pharmaceuticals Faces Setback in JZP150 Phase II T...

Jazz Pharmaceuticals recently released the top-line findings from Phase II trial...